Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug

Published: 2017-12-14 16:26:00
Updated: 2017-12-14 15:06:54

Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December.

The paper, generally managed by Circulatory Internal Medicine Professor Hyo-So...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.